指南与共识介入技术与安全PET

ACR-ACNM-ARS-ASTRO-SNMMI放射性药物治疗实践参数

ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals.
指南 / 共识 · Am J Clin Oncol · 2023-12-22

该实践参数由美国放射学会(ACR)、美国核医学学会、美国镭学会、美国放射肿瘤学会及核医学与分子影像学会协作修订,旨在为使用非密封源(放射性药物)进行治疗操作且需书面指令的授权用户提供资源。文件涵盖放射性药物治疗的一般原则、各类α、β、γ及混合发射药物的适应证,以及放射治疗团队成员的资质与职责、会诊与临床文档、治疗后随访、辐射安全、质量控制与改进、感染控制和患者教育等内容。

要点

  • 放射性药物包括元素放射性同位素或通过化学键整合到靶向分子中的放射性元素。
  • 文件涉及α、β、γ及混合发射药物的治疗适应证,并引用近期多个实践参数。
  • 明确授权用户、合格医学物理师及其他专业人员在放射性药物治疗中的角色与职责。

核心结论

  • 该文件涵盖临床情形、可用药物的要素、放射治疗团队各成员的资质与职责、会诊及其他临床文档的规范、治疗后随访、辐射安全预防措施、质量控制与改进计划的要素、感染控制以及患者教育,以确保使用放射性药物时的最佳患者照护与安全。

研究设计与样本

  • 该实践参数由ACR放射肿瘤学委员会实践参数-放射肿瘤学委员会与美国镭学会合作,按照ACR网站「制定ACR实践参数与技术标准的过程」所述流程制定。
  • 由美国放射学会(ACR)、美国核医学学会、美国镭学会、美国放射肿瘤学会和核医学与分子影像学会协作修订。

临床应用与阅片要点

  • 文件为经适当培训和许可、使用非密封源(文件中以更包容的术语「放射性药物」指代)进行治疗操作且根据NRC 10 CFR 35.300需要书面指令的授权用户提供资源。
  • 文件提供放射性药物治疗的一般原则以及各种α、β、γ和混合发射药物的适应证指导,并引用近期关于新型和常用放射性药物治疗的多个实践参数。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine, the American Radium Society, the American Society for Radiation Oncology, and the Society of Nuclear Medicine and Molecular Imaging. The document is intended to serve as a resource for appropriately trained and licensed physicians who perform therapeutic procedures with unsealed sources, referred to in the document using the more inclusive terminology of radiopharmaceuticals, for which a written directive is required for authorized users under NRC 10 CFR 35.300.

METHODS: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website ( https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards ) by the Committee on Practice Parameters-Radiation Oncology of the ACR Commission on Radiation Oncology in collaboration with the American Radium Society.

RESULTS: This practice parameter addresses the overall role of the applicable physician-authorized user, Qualified Medical Physicist, and other specialized personnel involved in the delivery of radiopharmaceutical therapy. Therapeutic radiopharmaceuticals include those administered as elemental radioactive isotopes (radionuclides) or the radioactive element incorporated into a targeting molecule (ligand) by one or more chemical bonds. This document provides guidance regarding general principles of radionuclide therapies and indications of various alpha, beta, gamma, and mixed emission agents with references to several recent practice parameters on new and commonly performed radiopharmaceutical therapies.

CONCLUSION: This document addresses clinical circumstances, elements of available agents, and the qualifications and responsibilities of various members of the radiation care team, specifications of consultation and other clinical documentation, post-therapy follow-up, radiation safety precautions, elements of quality control and improvement programs, infection control, and patient education to ensure optimal patient care and safety when utilizing radiopharmaceuticals.

来源:Am J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wallner PE, Yoo DC, Calais J, et al. ACR-ACNM-ARS-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radiopharmaceuticals. Am J Clin Oncol. 2023. PMID: 38131352. doi:10.1097/COC.0000000000001072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。